文献速递泌尿生殖与妇科肿瘤放疗

高危局限性前列腺癌放疗联合3年雄激素剥夺治疗加或不加每周多西他赛的2期随机研究

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-10-12

这项2期随机试验纳入132例高危局限性前列腺癌患者,比较标准治疗(黄体生成素释放激素类似物联合放疗,A组)与试验组(放疗+9周期每周多西他赛+3年雄激素剥夺治疗,B组)。两组60个月生化复发率、无进展生存率和5年总生存率均无统计学显著差异,同步每周多西他赛可安全给予且未显著增加毒性。

要点

  • 60个月生化复发率A组93.4% vs B组85.3%,差异无统计学显著(P=.3297)。
  • 60个月无进展生存率A组93.4% vs B组83.7%,差异无统计学显著(P=.2532)。
  • 同步每周多西他赛可安全联合标准剂量放疗,毒性未显著增加。

核心结论

  • 同步每周多西他赛可安全联合标准剂量放疗给予,毒性谱未见显著增加。
  • 在常规治疗基础上加用多西他赛后,5年无生化复发生存、无进展生存和总生存均未观察到统计学显著差异。

研究设计与样本

  • 2期随机试验,共纳入132例高危局限性前列腺癌患者。
  • 患者特征包括T3-T4期81.1%、Gleason评分≥8分77.3%、前列腺特异性抗原>20 ng/mL 28.9%、pN+ 18.2%。
  • A组为标准治疗对照臂:黄体生成素释放激素类似物联合放疗;B组为试验臂:放疗+9周期每周多西他赛+3年雄激素剥夺治疗。
  • 主要目标为随机化后5年内无生化复发的患者比例达到较高水平;次要终点包括无生化复发生存、无进展生存、总生存、临床缓解率、生化缓解率和毒性。

主要发现

  • 60个月生化复发率A组93.4% vs B组85.3%,差异无统计学显著(P=.3297)。
  • 60个月无进展生存率A组93.4% vs B组83.7%,差异无统计学显著(P=.2532)。
  • 5年生存率A组93.3%(95%CI 83.1-97.45)vs B组93.6%(95%CI 83.8-97.55);中位无进展生存和总生存均未达到。
  • 治疗结束后3个月前列腺特异性抗原≤0.2 ng/mL的患者比例A组81.25% vs B组90.48%,差异无统计学显著(P=.2028)。
  • 无生化复发生存两组间无显著差异;腹泻是主要非血液学毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 长期随访尚不足以达到中位无进展生存和总生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Docetaxel improves survival in patients with metastatic prostate cancer. This randomized phase 2 trial aimed to assess the activity of weekly docetaxel with radiation therapy (RT) plus androgen deprivation in patients with high-risk localized prostate cancer. The study examined the benefit of 9 weekly docetaxel administrations to RT plus 3 years of luteinizing hormone-releasing hormone analogues. METHODS AND MATERIALS: A total of 132 patients were recruited for the study. Patients' characteristics included T3-T4 stage (81.1%), Gleason score ≥8 (77.3%), prostate-specific antigen level >20 ng/mL (28.9%), and pN+ (18.2%). All patients included in the trial received either the standard-of-care control arm with luteinizing hormone-releasing hormone analogues plus RT (arm A) or the experimental arm (RT + 9 weekly cycles of docetaxel + 3 years of androgen deprivation therapy, arm B). The primary objective was to achieve a high percentage of patients who were free of biochemical recurrence within 5 years of randomization. Secondary endpoints included biochemical recurrence-free survival (BRFS), progression-free survival (PFS), overall survival (OS), clinical response rate, biochemical response rate, and toxicity. RESULTS: No difference between the arms of the study was found in biochemical recurrence (93.4% at 60 months for arm A vs 85.3% for arm B; P = .3297). PFS at 60 months was 93.4% and 83.7% in arms A and B, respectively (P = .2532). Five-year survival was 93.3% (95% confidence interval, 83.1-97.45) in arm A versus 93.6% (83.8-97.55) in arm B; median PFS and OS have not been reached. Prostate-specific antigen level ≤0.2 ng/mL at 3 months after the end of treatment was seen in 81.25% of patients in arm A compared with 90.48% of patients in arm B (P = .2028). BRFS was not significantly different between treatment arms. Diarrhea was the main nonhematologic toxicity. Long-term follow-up has not yet been enough to meet median PFS and OS. CONCLUSIONS: Concurrent weekly docetaxel can be administered safely with standard doses of RT without a significant increase in the toxicity profile. No statistically significant differences for 5-year BRFS, PFS, and OS have been observed when docetaxel was added to conventional treatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Carles J, Gallardo E, Doménech M, et al. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. Int J Radiat Oncol Biol Phys. 2018. PMID: 30321689. doi:10.1016/j.ijrobp.2018.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。